INTRODUCTION
HISTORY
MAIN LEADERS
DEPARTMENTS
SPECIALISTS
RESEARCH
EDUCATION
PREVENTION
HONOUR
INTERNATIONAL
 You are here: Home >specialists>  Desen Wan
 Professor  Desen Wan

     Desen Wan, M.D. Professor, Director of the Department of Abdominal oncology, Chief of WHO Cancer Research Collaborating Center, Member of Executive Committee of Chinese Anticancer Association.                     
     Dr. Wan received his M.D. from Sun Yat-Sen University of Medical Sciences (SUMS) in 1965. Since then he has been working in the fields of patient care, cancer prevention, cancer  research and  medical education in Cancer Center, SUMS.  Dr. Wan was selected as a  "Young scientist with outstanding contribution” by  the  MPH in 1986.  Sponsored by WHO scholarship,  Dr. Wan took part in the training project for  oncologists  in  USA in 1989,  majoring in research  and  management of gastrointestinal tumors. He was promoted to be professor in  1991  and  doctorate  supervisor  in  1997. He  is  a former director of our Cancer Center. His interests are in cancer screening in community,  early  diagnosis  and  treatment of  colorectal  cancer, and prevention of liver metastasis of large bowel cancer. There are six ongoing projects under the charge of Dr. Wan supported by various grants.

Recent publications:
  

     High dose intraarterial hepatic infusion chemotherapy  with drug filtration (HIA-F) for  primary liver  cancer.Chinese Med J 1990; 70(6): 355.
     Expression of C-erbB-2/neu proto-oncogene in human prostate cancer tissue and cell lines. Molecular Carcinogenesis 1992; 5: 320-327.
     Assaying serum drug concentration in mesenteric and peripheral veins after intraluminal fluorouracil chemotherapy: an
     exploration of mechanism on intraluminal chemotherapy. Chinese J Cancer 1990; 9(30: 189.
     Assay on the half-life of serum  AFP after hepatectomy for primary liver cancer and its clinical value: a prospective
     clinical study. Chinese j Digestion 1995; 15(4): 206-208.
     High dose intraarterial hepatic infusion chemotherapy with drug filtration (HIA-F) for primary liver cancer: a preliminary  report. Regional Cancer Treat 1994; 7: 208-210.
     Telomerase activity and its clinicobiologic significance in human large bowel cancer. Chinese J Cancer 1998; 17(1):
     35-37.
     Advance on treatment of liver metastases from colorectal cancer. Chinese J Cancer 1997; 16(1): 1-4.
 
Address:
         Department of Abdominal Oncology,
         Sun Yat-Sen University Cancer Center,
         651 Dongfeng East Road
         Guangzhou  510060
         P. R. China
         Tel:  +86-20-87343125 
         Fax:  +86-20-87343392